Skip to main content
Premium Trial:

Request an Annual Quote

GenMark Diagnostics: James McNally

GenMark Diagnostics said that on Jan. 9, it notified James McNally, its senior vice president of marketing and business development, that his employment with the firm would cease on Jan. 10.

In a filing with the US Securities and Exchange Commission, GenMark also said that on Jan. 14, it entered into a separation agreement and general release with McNally. In accordance with the agreement, McNally is entitled to benefits, including a gross lump sum payment equal to six months of his base salary in effect as of the separation date; an amount equal to McNally’s target bonus percentage under the firm's 2019 bonus plan multiplied by a percentage tied to the achievement of the company-level performance targets under the plan; and an aggregate of 35,702 restricted stock units held by McNally as of the separation date.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.